PANACEABIO — Panacea Biotec Balance Sheet
0.000.00%
- IN₹27.35bn
- IN₹25.74bn
- IN₹5.59bn
- 54
- 15
- 59
- 36
Annual balance sheet for Panacea Biotec, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,487 | 5,493 | 2,075 | 1,514 | 1,462 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 867 | 1,338 | 1,096 | 1,114 | 1,384 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,110 | 9,906 | 5,683 | 4,852 | 5,452 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,279 | 6,255 | 6,163 | 6,348 | 6,369 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 11,775 | 17,589 | 12,712 | 12,407 | 12,897 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,491 | 7,764 | 3,318 | 3,088 | 3,670 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 14,062 | 8,822 | 4,276 | 3,986 | 4,550 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2,287 | 8,766 | 8,436 | 8,420 | 8,348 |
| Total Liabilities & Shareholders' Equity | 11,775 | 17,589 | 12,712 | 12,407 | 12,897 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |